Deng YF, Cui XS, Wang L. Reconceptualization of immune checkpoint inhibitor-associated gastritis. World J Gastroenterol 2024; 30(36): 4031-4035 [PMID: 39351252 DOI: 10.3748/wjg.v30.i36.4031]
Corresponding Author of This Article
Liang Wang, MD, Attending Doctor, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. wangliang19911128@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 28, 2024; 30(36): 4031-4035 Published online Sep 28, 2024. doi: 10.3748/wjg.v30.i36.4031
Reconceptualization of immune checkpoint inhibitor-associated gastritis
Ying-Fang Deng, Xian-Shu Cui, Liang Wang
Ying-Fang Deng, Xian-Shu Cui, Department of Oncology, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Ying-Fang Deng, Xian-Shu Cui, Ying-Fang Deng and Xian-Shu Cui.
Liang Wang, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Author contributions: Deng YF and Cui XS co-wrote the manuscript, sharing the first authorship; Wang L contributed to the editorial concept and design; Deng YF and Cui XS reviewed the literature; Wang L revised and reviewed the manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Liang Wang, MD, Attending Doctor, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. wangliang19911128@163.com
Received: July 24, 2024 Revised: August 28, 2024 Accepted: September 9, 2024 Published online: September 28, 2024 Processing time: 57 Days and 19.7 Hours
Core Tip
Core Tip: With the widespread application of immunotherapy, the incidence of immune-related gastritis has increased than before. However, the diagnosis of immune-related gastritis is somewhat challenging due to its atypical clinical symptoms and lack of specific findings in serological tests. Although endoscopy and histopathological examination are valuable for immune-related gastritis diagnosis, differential diagnosis for different diseases (such as autoimmune gastritis) is still necessary. The treatment of immune-related gastritis should be individualized based on the patient's specific situation. The occurrence and management of immune-related adverse events (irAEs), as well as whether to continue treatment with immune checkpoint inhibitors (ICIs) after resolution, are major challenges in clinical practice. Studies have shown that for patients with grade 2-3 irAEs, ICI treatment can be considered for reinitiation when symptoms regress to grade 0-1, preferably using a different class of ICIs. For grade 4 irAEs, ICIs should be permanently discontinued.